厄贝沙坦治疗原发性高血压合并左心室肥厚的疗效和安全性的系统评价

Therapeutic Efficacy and Safety of Irbesartan for Primary Hypertensive Patients with Left Ventricle Hypertrophy:a Systematic Review

目的:系统评价厄贝沙坦治疗原发性高血压合并左心室肥厚的疗效和安全性。方法:计算机检索中国期刊全文数据库、万方数据库、维普数据库、中国生物医学文献数据库等,纳入厄贝沙坦治疗原发性高血压合并左心室肥厚的随机对照试验(RCT),使用RevMan5.1软件进行系统评价。结果:纳入8项RCT,合计648例患者。Meta分析结果显示,厄贝沙坦组改善左心室肥厚的疗效优于对照组[MD=8.51,95%CI(4.16,12.86),P<0.01];2组降压疗效比较差异无统计学意义[RR=1.03,95%CI(0.93,1.13),P=0.59];厄贝沙坦组不良反应发生率低于对照组[RR=0.43,95%C(I0.22,0.83),P=0.01]。结论:厄贝沙坦治疗原发性高血压合并左心室肥厚降压疗效较好,不良反应少。

OBJECTIVE： To evaluate the efficacy and safety of irbesartan for primary hypertensive patients with left ventricle hypertrophy. METHODS： Retrieved from CNKI, Wanfang database, VIP and CBM, RCTs about irbesartan for primary hyperten- sive patients with left ventricle hypertrophy were included, and systematic review was conducted by using Rev Man 5.1 software. RESULTS： 8 RCTs were included, involving 648 patients. Meta-analysis showed that irbesartan was superior to control group in improving left ventricle hypertrophy[MD=8.51,95 % CI （4.16, 12.86 ）, P〈 0.01 ] ; there was no statistical significance in controlling blood pressure between 2 groups[RR= 1.03, 95 % CI （0.93, 1.13）, P= 0.59]; the incidence of ADR in irbesartan group was lower than in control group [RR= 0.43,95 % CI（0.22,0.83）,P=0,01]. CONCLUSION： Irbesartan have better efficacy and safety than oth- er antihypertensive drugs in the treatment of primary hypertension complicating with left ventricle hypertrophy.